業績

{ 102件 }

Aika Miya, Akinobu Nakamura, Hiroshi Nomoto, Hiraku Kameda, Tatsuya Atsumi Positive association between the proinsulin-to-C-peptide ratio and prolonged hyperglycemic time in type 2 diabetes Endocrine Journal, in press.

IF=2.0

  • 2024
  • 糖尿病・内分泌グループ
  • 欧文論文/原著

Iesaka H, Kameda H, Miya A, Nomoto H, Cho KY, Nakamura A, Abe T, Shinohara N, Atsumi T Fulminant ACTH decrease following diabetic ketoacidosis induced by immune checkpoint inhibitor combination therapy with nivolumab and

ipilimumab: A case report

Medicine, in press

IF: 1.6

  • 2023
  • 糖尿病・内分泌グループ
  • 欧文論文/症例報告

Izumihara R, Nomoto H*, Kito K, Yamauchi Y, Omori K, Shibayama Y, Yanagiya S, Miya A, Kameda H, Cho KY, Nagai S, Sakuma I, Nakamura A, Atsumi T.

Switching from conventional fibrates to pemafibrate has beneficial effects on the renal function of diabetic subjects with chronic kidney disease.

Diabetes Metab J, in press.

IF: 5.9, 5-Y IF: 5.4

  • 2023
  • 糖尿病・内分泌グループ
  • 欧文論文/原著

Sho Furusawa, Hiroshi Nomoto,  Hiroki Yokoyama,  Yuka Suzuki, Atsushi Tsuzuki, Kiyohiko Takahashi, Aika Miya, Hiraku Kameda,  Kyu Yong Cho, Jun Takeuchi, So Nagai, Shinji Taneda, Yoshio Kurihara, Akinobu Nakamura, Tatsuya Atsumi.

Glycemic control efficacy of switching from dipeptidyl peptidase-4 inhibitors to oral semaglutide in subjects with type 2 diabetes: a multicenter, prospective, randomized, open-label, parallel-group comparison study (SWITCH-SEMA 2 study) Diabetes, Obesity and Metabolism, in press

IF=5.8

  • 2023
  • 糖尿病・内分泌グループ
  • 欧文論文/原著

Akinobu Nakamura, Aika Miya, Yuka Suzuki, Hiroshi Nomoto, Hiraku Kameda, Kyu Yong Cho, So Nagai, Tatsuya Atsumi.

Positive association between proinsulin and fatty liver index in people with type 2 diabetes.

Endocr J, in press.

IF: 2.0

  • 2023
  • 糖尿病・内分泌グループ
  • 欧文論文/原著

Nomoto H, Kito K, Iesaka H, Handa T, Yanagiya S, Miya A, Kameda H, Cho KY, Takeuchi J, Nagai S, Sakuma I, Nakamura A, Atsumi T.

Preferable Effects Of Pemafibrate On Liver Function And Fibrosis In Subjects With Type 2 Diabetes Complicated With Liver Damage Diabetol Metab Syndr, in press IF= 4.7

  • 2023
  • 糖尿病・内分泌グループ
  • 欧文論文/原著

Sekizaki T, Kameda H, Nakamura A, Kuwabara S, Nomoto H, Cho KY, Ishi Y, Motegi H, Miyoshi H, Atsumi T.

Neuromedin B receptor as a potential therapeutic target for corticotroph adenomas Pituitary, in press IF = 3.8

  • 2023
  • 糖尿病・内分泌グループ
  • 欧文論文/原著

Nomoto H, Takahashi Y,  Takano Y, Yokoyama H, Tsuchida K, Nagai S, Miya A, Kameda H, Cho KY, Nakamura A, Atsumi T.

Effect of switching to once-weekly semaglutide on non-alcoholic fatty liver disease: The SWITCH-SEMA 1 subanalysis Pharmaceutics, in press IF = 5.4, 5-Y IF= 6.0

  • 2023
  • 糖尿病・内分泌グループ
  • 欧文論文/原著

96回日本内分泌学会学術集会 愛・内分泌賞 大江 悠希先生

  • 2023
  • 糖尿病・内分泌グループ
  • 受賞

Favorable effect of pemafibrate on insulin resistance and β-cell function in subjects with type 2 diabetes and hypertriglyceridemia: a subanalysis of the PARM-T2D study Hiroshi Nomoto, Kenichi Kito, Hiroshi Iesaka, Yuki Oe, Shinichiro Kawata, Kazuhisa Tsuchida, Shingo Yanagiya, Aika Miya, Hiraku Kameda, Kyu Yong Cho, Ichiro Sakuma, Naoki Manda, Akinobu Nakamura, Tatsuya Atsumi Pharmaceutics, in press IF 6.525

  • 2023
  • 糖尿病・内分泌グループ
  • 欧文論文/原著